Financhill
Back

Allogene Therapeutics Stock Predictions

Allogene Therapeutics Stock Forecast

  • Is Allogene Therapeutics Stock Undervalued?
    The current Allogene Therapeutics [ALLO] share price is $2.91. The Score for ALLO is 50, which is 0% below its historic median score of 50, and infers higher risk than normal.
  • ALLO is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.

Will Allogene Therapeutics Stock Go Up Next Year?

Data Unavailable

Allogene Therapeutics Stock Rating

Data Unavailable

Allogene Therapeutics Stock Price History

Is ALLO stock going to rise?

  • The current trend is moderately bullish and ALLO is experiencing selling pressure, which indicates risk of future bearish movement.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
United States
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
allogene.com

52-Week Data

52-Week High:
5.78
52-Week Low:
2.01

Prediction Charts

Market Cap:
608.51M
Price in USD:
2.91
Volume:
4.6M
Beta:
0.91

Technical Analysis

SMA50:
2.72
SMA100:
2.64
SMA200:
3.22
52-Wk Change:
-25.58%

Stock Predictions

  • Is Allogene Therapeutics stock public?
    Yes, Allogene Therapeutics is a publicly traded company.
  • What is the Allogene Therapeutics stock quote today?
    The Allogene Therapeutics stock price is 2.91 USD today.
  • How to buy Allogene Therapeutics stock online?
    You can buy Allogene Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Aug-30 2.68 2.63 2.73 2.58
Sep-3 2.58 2.51 2.71 2.48
Sep-4 2.49 2.58 2.59 2.47
Sep-5 2.58 2.51 2.64 2.49
Sep-6 2.51 2.40 2.57 2.37
Sep-9 2.41 2.48 2.52 2.39
Sep-10 2.48 2.83 2.84 2.46
Sep-11 2.80 2.92 2.93 2.67
Sep-12 2.90 2.67 2.97 2.64
Sep-13 2.69 2.96 2.98 2.69
Sep-16 2.97 2.76 2.97 2.71
Sep-17 2.78 2.88 2.90 2.64
Sep-18 2.91 2.88 3.03 2.78
Sep-19 3.02 2.91 3.07 2.86

Allogene Therapeutics Earnings

Data Unavailable

Allogene Therapeutics Forecast Revenue Growth

Data Unavailable

  • Analysts estimate an earnings increase this quarter of $0.20 per share, a decrease next quarter of $0.08 per share, an increase this year of $0.57 per share, and a decrease next year of $0.10 per share.

* Allogene Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.